Latest Breaking News On - Santhera pharmaceuticals holding - Page 6 : comparemela.com

Santhera Pharmaceuticals Holding AG: Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage

Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF) Short Interest Update

Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF – Get Free Report) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 136,400 shares, a growth of 69.0% from the October 15th total of 80,700 shares. Based on an average trading volume of 1,300 shares, the short-interest […]

Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Ad hoc announcement pursuant to Art. 53 LR Food and Drug Administration (FDA) approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in children and adults aged 2 years and olderU.S. license holder Catalyst Pharmaceuticals plans for commercial launch in Q1-2024FDA approval triggers USD 36 million payment obligation from Catalyst to Santhera, of which USD 26 million will be used to cover Santhera’s third-party milestone obligationsFollowing the recent positive CHMP

Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval

By Ben Glickman Catalyst Pharmaceuticals said that it would commercially launch Agamree, a treatment for Duchenne Muscular Dystrophy, after the treatment was.

The 68% return this week takes Santhera Pharmaceuticals Holding's (VTX:SANN) shareholders one-year gains to 96%

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right.